Trial Profile
A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Oral Food Challenge Trial of Xolair (Omalizumab) in Peanut Allergy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 10 May 2014 New trial record